The prognosis for patients who experience hemostatic complications after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is poor. However, no report has investigated disseminated intravascular coagulation (DIC) caused by the complications of allo-HSCT without infection. Recombinant human soluble thrombomodulin (rhTM) was used to treat 12 episodes of DIC (n = 10; group 1) caused by allo-HSCT complications such as acute graft-versus-host disease (aGVHD) or thrombotic microangiopathy (TMA), and the clinical outcomes were compared with those of historical controls (n = 9; group 2) treated for DIC without rhTM. In group 1, the mean DIC score was significantly improved after using rhTM. Fibrinogen degeneration product (FDP), C-reactive protein (CRP), and the inflammatory cytokine high-mobility group box 1 (HMGB1) were also significantly decreased. Serial changes from the baseline values of platelet counts and levels of FDP were significantly better in group 1 than in group 2. The recovery rate from DIC was significantly higher in group 1 than in group 2. These findings suggest that rhTM is effective against both DIC and systemic inflammatory complications after allo-HSCT.

1.
Levi M, Ten Cate H: Disseminated intravascular coagulation. N Engl J Med 1999; 341: 586–592.
2.
Levi M, Toh CH, Thachil J, Watson HG: Guidelines for the diagnosis and management of disseminated intravascular coagulation. Br J Haematol 2009; 145: 24–33.
3.
Abeyama K, Stern M, Ito Y, Kawahara K, Yoshimoto Y, Tanaka M, et al: The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel anti-inflammatory mechanism. J Clin Invest 2005; 115: 1267–1274.
4.
Wada H, Gabazza EC, Asakura H, Koike K, Okamoto K, Maruyama I, et al: Comparison of diagnostic criteria for disseminated intravascular coagulation (DIC): Diagnostic Criteria of the International Society of Thrombosis and Hemostasis (ISTH) and of the Japanese Ministry of Health and Welfare for Overt DIC. Am J Haematol 2003; 74: 17–22.
5.
Glucksberg H, Storb R, Ferfer A, Buckner CD, Neiman PE, Clift RA, et al: Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295–304.
6.
Ho VT, Cutler C, Carter S, Martin P, Adams R, Horowitz M, et al: Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 571–575.
7.
Hong KT, Kang HJ, Kim NH, Kim MS, Lee JW, Kim H, et al: Peri-engraftment syndrome in allogeneic hematopoietic SCT. Bone Marrow Transplant 2013; 48: 523–528.
8.
Pihusch R, Salat C, Schmidt E, Göhring P, Pihusch M, Hiller E, et al: Hemostatic complications in bone marrow transplantation: a retrospective analysis of 447 patients. Transplantation 2002; 74: 1303–1309.
9.
Bacigalupo A: Haemopoietic stem cell transplants: the impact of haemorrhagic complications. Blood Rev 2003; 17:S6–S10.
10.
Pinomaki A, Volin L, Korhonen LJ, Virtanen JO, Lemponen M, Ruutu T, Lassila R: Early thrombin generation and impaired fibrinolysis after SCT associate with acute GVHD. Bone Marrow Transplant 2010; 45: 730–737.
11.
Esmon CT: The role of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 1989; 264: 4743–4746.
12.
Suzuki K, Kusumoto H, Deyashiki Y, Nishioka J, Maruyama I, Zushi M, et al: Structure and expression of human thrombomodulin, a thrombin receptor on endothelium acting as a cofactor for protein C activation. EMBO J 1987; 6: 1981–1997.
13.
Zushi M, Gomo K, Yamamoto S, Maruyama I, Hayashi T, Sazuki K: The last three consecutive epidermal growth factor-like structures of human thrombomodulin comprise the minimum functional domain for protein C-activating cofactor activity and anticoagulant activity. J Biol Chem 1989; 254: 10351–10353.
14.
Gibot S, Massin F, Cravoisy A, Barraud D, Nace L, Levy B, Bollaert PE: High-mobility group box 1 protein plasma concentrations during septic shock. Intensive Care Med 2007; 33: 1347–1353.
15.
Nagato M, Okamoto K, Abe Y, Higure A, Yamaguchi K: Recombinant human soluble thrombomodulin decreases the plasma high-mobility group box-1 protein levels, whereas improving the acute liver injury and survival rates in experimental endotoxemia. Crit Care Med 2009; 37: 2181–2186.
16.
Ombrellino M, Wang H, Ajemian MS, Talhouk A, Scher AL, Friedman GS, Tracy KJ: Increased serum concentrations of high–mobility group protein 1 in haemorrhagic shock. Lancet 1999; 354: 1446–1447.
17.
Huang LF, Yao YM, Dong N, Yu Y, He LX, Sheng ZY: Association of high mobility group box-1 protein levels with sepsis and outcome of severely burned patients. Cytokine 2011; 53: 29–34.
18.
Yasuda T, Ueda T, Takeyama Y, Shinzeki M, Sawa H, Nakajima T, et al: Significant increase of serum high-mobility group box chromosomal protein 1 levels in patients with severe acute pancreatitis. Pancreas 2006; 33: 359–363.
19.
Inoue Y, Saito T, Ogawa K, Nishio Y, Kosugi S, Suzuki Y, et al: Role of serum high mobility group box 1 in hematological malignancies complicated with systemic inflammatory response syndrome and effect of recombinant thrombomodulin. Leuk Lymphoma 2013; 54: 1953–1958.
20.
Inoue Y, Kosugi S, Miura I, Hatta Y, Takeuchi J: Successful treatment of refractory acute GVHD complicated by severe intestinal transplant-associated thrombotic microangiopathy using recombinant thrombomodulin. Thrombosis Res 2011; 127: 603–604.
21.
Ikezoe T, Togitani K, Komatsu N, Isaka M, Yokoyama A: Successful treatment of sinusoidal obstructive syndrome after hematopoietic stem cell transplantation with recombinant human soluble thrombomodulin. Bone Marrow Transplant 2010; 45: 783–785.
22.
Sakai M, Ikezoe T, Bandobashi K, Togitani K, Yokoyama A: Successful treatment of transplantation-associated thrombotic microangiopathy with recombinant human soluble thrombomodulin. Bone Marrow Transplant 2010; 45: 803–805.
23.
Nomura S, Ishii K, Fujita S, Nakaya A, Satake A, Ito T: Associations between acute GVHD-related biomarkers and endothelial cell activation after allogeneic hematopoietic stem cell transplantation. Transpl Immunol 2017; 43–44: 27–32.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.